Elanco Animal Health (ELAN) Tops Q4 EPS by 88c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results
February 24, 2022 6:30 AM ESTFull year 2021 revenue was $4,765 million, an increase of 46 percent, including $1,311 million of incremental revenue from Bayer Animal Health products in 2021. Full year 2021 earnings per share (EPS) was $(0.97) (reported), or $1.05 (adjusted). Fourth quarter 2021 revenue was $1,113 million, a decline of 2 percent. Excluding the unfavorable impact of $60 million of previously disclosed items that benefited the fourth quarter of 2020 and the unfavorable impact of foreign exchange rates, fourth quarter 2021 revenue increased 4 percent. Fourth quarter 2021 EPS was $(0.20) (reported), or $0.21 (adjusted), an increase of 70 percent as reported and 75 percent on an adjusted basis. Providing financial... More
